Grufity logoGrufity logo
Stocks
Funds
Screener
Sectors
Watchlists
OGN

OGN - Organon & Co. Stock Price, Fair Value and News

$8.88-0.12 (-1.33%)
Market Closed

75/100

OGN

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

75/100

OGN

STOCK SCORE

High Scoring Large Cap stocks have outperformed low scoring stocks by 90% over last 10 years

Price Targets

Target 1Y

$14.59

Target 3M

$10.79

Target 6M

$11.94

OGN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

OGN Price Action

Last 7 days

-7.4%

Last 30 days

24.9%

Last 90 days

35.2%

Trailing 12 Months

-44.7%

OGN RSI Chart

OGN Stock Valuation Analysis

Valuation

Login to View

Max Portfolio %

Login to View

OGN Valuation

Market Cap

2.3B

Price/Earnings (Trailing)

4.61

Price/Sales (Trailing)

0.37

EV/EBITDA

7.66

Price/Free Cashflow

2.97

OGN Price/Sales (Trailing)

The Good, Bad and Ugly

Growth

Profitability

Size

Dilution Risk

Balance Sheet

Momentum

Funds Popularity

Insider Trading

Price Targets

Target 1Y

$14.59

Target 3M

$10.79

Target 6M

$11.94

OGN Fundamentals

OGN Revenue

Revenue (TTM)

6.3B

Rev. Growth (Yr)

1.26%

Rev. Growth (Qtr)

0.5%

OGN Earnings

Earnings (TTM)

501.0M

Earnings Growth (Yr)

-55.43%

Earnings Growth (Qtr)

10.34%

OGN Profitability

EBT Margin

11.14%

Return on Equity

55.3%

Return on Assets

3.7%

Free Cashflow Yield

33.66%

OGN Investor Care

Dividend Yield

6.76%

Dividend/Share (TTM)

0.6

Shares Dilution (1Y)

0.95%

Diluted EPS (TTM)

1.92

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20256.3B6.3B6.3B0
20246.3B6.3B6.4B6.4B
20236.1B6.2B6.2B6.3B
20226.4B6.4B6.3B6.2B
20216.3B6.3B6.3B6.3B
20207.5B7.2B6.8B6.5B
20190007.8B
Get all data in R, Python etc through our Historical Stock Data APIs

About Organon & Co.

OGN
Organon & Co. develops and delivers health solutions through a portfolio of prescription therapies and medical devices within women's health in the United States and internationally. Its women's health portfolio comprises contraception and fertility brands, such as Nexplanon/Implanon, a long-acting reversible contraceptive; Nuvaring, a monthly vaginal contraceptive ring; Cerazette, a daily pill used to prevent pregnancy; Marvelon, progestin and estrogen used as daily pills to prevent pregnancy; Follistim AQ, used to promote the development of multiple ovarian follicles in assisted reproduction technology procedures; Elonva, an ovarian follicle stimulant; Ganirelix Acetate Injection, an injectable antagonist; and Jada, for abnormal postpartum uterine bleeding or hemorrhage. The company's biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; and two oncology products, including Ontruzant and Aybintio. It offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Rosuzet, and Zocor brands; Cozaar and Hyzaar for the treatment of hypertension; respiratory products for treatments of control and prevent symptoms caused by asthma under the Singulair, Dulera, Zenhale, and Asmanex brand names; and Singulair, Nasonex, Clarinex, and Aerius for treating seasonal allergic rhinitis. The company provides dermatology products under the Diprosone and Elocon brand; bone health portfolio, including Fosamax brand name; non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brand names; Proscar for the treatment of symptomatic benign prostatic hyperplasia; and Propecia for the treatment of male pattern hair loss. The company sells its products to drug wholesalers and retailers, hospitals, pharmacies, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. The company was incorporated in 2020 and is headquartered in Jersey City, New Jersey.
 CEO
 WEBSITEorganon.com
 SECTORHealthcare
 INDUSTRYDrug Manufacturers General
 EMPLOYEES10000

Organon & Co. Frequently Asked Questions

OGN is the stock ticker symbol of Organon & Co.. Every public company that trades on a stock exchange gets a ticker symbol.

As of Wed Jan 28 2026, market cap of Organon & Co. is 2.31 Billion. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

You can check OGN's fair value in chart for subscribers.

The fair value guage provides a quick view whether OGN is over valued or under valued. Whether Organon & Co. is cheap or expensive depends on the assumptions which impact Organon & Co.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for OGN.

As of Wed Jan 28 2026, OGN's PE ratio (Price to Earnings) is 4.61 and Price to Sales (PS) ratio is 0.37. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. OGN PE ratio will change depending on the future growth rate expectations of investors.